US medtech valuations have compressed deeply, but fundamentals have not broken down

Overview

This Bernstein Weekend Healthcare Pulse focuses on the ongoing slump in the US medtech sector. The report notes that US medtech stocks have significantly underperformed the S&P 500 over the past year, with sector valuation multiples falling to multi-year lows, but the authors do not believe this reflects a collapse in industry fundamentals. Instead, the report argues that medtech companies still operate in attractive oligopolistic markets, innovation continues to advance, procedure volumes and demand remain solid, and the main issue is that the investment stories of many core stocks have become more complicated, while the market has had little patience for complex medtech narratives during the strength of the AI theme.

Core views

The core view is that medtech weakness looks more like a 'narrative discount' than a 'fundamental discount.' Concerns about slowing procedure volumes, cost pressures from oil, resin, semiconductors, and memory, and the potential impact of GLP-1 on end markets are all considered insufficient by the report to explain the sector's deep decline. The real drag comes from company-specific events and execution risks across multiple names, including slower Watchman and EP growth at BSX and its large Penumbra acquisition, ABT's nutrition pricing reset and structural heart share pressure, SYK's cyberattack, PODD's manufacturing issues and FDA communication impact, MDT's pressure to deliver on new products, and ISRG appearing more expensive after sector valuations moved lower. As these single-stock risks are gradually removed, the report expects the sector to have a chance for a gradual recovery.

Analysis framework

The report uses a combination of top-down and bottom-up analysis: it first compares US medtech performance versus the S&P 500 and other healthcare subsectors, then examines the degree of compression in industry P/E and P/S multiples; it next breaks down, company by company, the recent events that have complicated investment narratives; and finally tests whether macro and thematic concerns such as procedure volumes, margins, and GLP-1 have actually harmed fundamentals, before proposing possible catalysts for sector recovery.

Methodology notes

• Relative Performance AnalysisSector Performance Relative to the S&P 500

  Measures capital preference and sector pressure using the relative returns of the medtech sector versus the S&P 500 and other healthcare subsectors.

  The report emphasizes that US medtech underperformed the S&P 500 by about 4,600 bps to nearly 5,000 bps over the past 12 months, indicating that the issue is not only absolute declines but also a pronounced loss of favor relative to both the broader market and healthcare internally.

• Valuation AnalysisHistorical Percentile Comparison of P/E and P/S

  Compares current valuations with 5-year and 10-year averages as well as late-2024 levels to assess the degree of valuation compression.

  The report shows that valuation multiples for most covered companies have fallen 25%-60% over the past 18 months; for example, BSX's current P/E is about 12.5x, down about 62% from late 2024.

• Fundamental VerificationElimination Approach to Thematic Concerns

  Checks one by one whether market concerns around procedure volumes, margins, and GLP-1 amount to a sector-wide deterioration in fundamentals.

  Citing management commentary from JNJ, SYK, UNH, ABT, ZBH, and others, the report argues that underlying demand remains solid, cost pressures are currently manageable, and the GLP-1 impact is not yet sufficient to explain the sector's sharp decline.

• Catalyst AnalysisPath to Removal of Single-Stock Risks

  Focuses on whether company-level execution, recalls, cyberattacks, M&A integration, and signs of growth bottoming gradually improve.

  The report believes that the removal of risks at SYK, ABT, ISRG, and especially BSX will help restore market confidence in the medtech sector.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• US medtech sector

  Core subject of the report

  Strengths

  Procedure volumes and underlying demand remain solid, the industry operates in attractive oligopolistic markets, innovation is fast, and long-term structural growth drivers remain intact.

  Weaknesses

  It has significantly underperformed the market over the past year, valuation multiples have compressed rapidly, and the market's tolerance for complex single-stock narratives has declined.

  Comparison

  It has underperformed the S&P 500 by about 4,600 bps to nearly 5,000 bps over the past 12 months, lagging other healthcare subsectors.

  Risks

  If the AI theme continues to absorb capital, or if single-stock risks are not removed as expected, sector valuations may remain under pressure.

• Boston Scientific (BSX)

  One of the key names for restoring confidence in the sector

  Strengths

  It had built credibility for high-single-digit growth, and Farapulse and Watchman drove a meaningful acceleration in organic growth in 2024-2025.

  Weaknesses

  EP and Watchman growth have slowed, FY26 organic growth guidance was cut from 10%-11% to 6.5%-8.0%, and the Penumbra and MiRus deals have raised concerns.

  Comparison

  P/E fell from above 36x in early 2025 to 12.5x, sharply down from about 32.7x at the end of 2024.

  Risks

  Unclear bottom in Watchman and EP growth, insufficient credibility in the reset long-term plan, and controversy over M&A integration and capital allocation.

• Abbott (ABT)

  A case of increasingly complicated single-stock narrative

  Strengths

  It has long-term growth opportunities in CGM and EP, and management expects the nutrition business to return to growth in the second half.

  Weaknesses

  4Q25 organic sales growth slowed to 3.0%, the nutrition business declined 9%, CGM sales slowed, and the structural heart business lost share.

  Comparison

  Down about 26% year to date; rated Outperform in the Ticker table, with a target price of $110.00.

  Risks

  Nutrition recovery may disappoint, the CGM market may remain weak, and structural heart share pressure may continue.

• Stryker (SYK)

  A representative case of execution risk caused by a cyberattack

  Strengths

  Management continues to emphasize that procedure volumes, hospital capital spending, and the order book remain solid, and expects revenue recognition and backlog recovery to provide support.

  Weaknesses

  A cyberattack on March 11 disrupted global operations, and 1Q26 organic growth was only 2.4%, about 5 percentage points below consensus expectations.

  Comparison

  Down about 10% year to date; rated Outperform in the Ticker table, with a target price of $410.00.

  Risks

  It needs to deliver about 11% organic growth in 2H26; if recovery is slower than expected, the credibility of full-year guidance may be damaged.

• Insulet (PODD)

  A weak name driven by recall and competition concerns

  Strengths

  Omnipod 5 remains an important diabetes device platform, and some manufacturing issues have been addressed through notices and free replacements.

  Weaknesses

  Investors are concerned about competing patch pumps and pharmacy channel pricing pressure, while voluntary medical device correction events in March and May added to the pressure.

  Comparison

  Down about 46% year to date; rated Outperform in the Ticker table, with a target price of $200.00.

  Risks

  Communication around serious adverse events, FDA wording, manufacturing quality, and competitive pressure may continue to weigh on valuation.

• Medtronic (MDT)

  A case of new product cycle and EPS delivery pressure

  Strengths

  FY27 has several high-profile launches, including Affera, RDN, Altaviva, and Hugo.

  Weaknesses

  Long-term TAVR data were disappointing, the MiniMed IPO fell short of expectations, and EPS growth has been weak over the past four years.

  Comparison

  Down about 16% year to date; rated Outperform in the Ticker table, with a target price of $97.00.

  Risks

  If FY27 new product ramp and EPS growth fail to deliver, valuation recovery may be constrained.

• Intuitive Surgical (ISRG)

  A name with strong fundamentals but valuation dragged by the sector

  Strengths

  1Q26 sales growth of 23% and EPS growth of 38% were both significantly above consensus, with estimates likely continuing to move higher.

  Weaknesses

  After sector valuations moved lower, its roughly 36x P/E still triggers valuation concerns.

  Comparison

  When BSX once traded at 35x P/E, the market could accept ISRG at over 70x; after BSX fell to 12.5x, ISRG looks relatively more expensive.

  Risks

  Sustainability of procedure volumes, remanufactured instruments, Chinese competitors, and competition from new systems from MDT/JNJ.

• PENUMBRA INC / PEN.US

  Mentioned as the asset BSX is acquiring for about $14.5 billion

  Strengths

  The report does not provide an independent fundamental assessment of PENUMBRA INC.

  Weaknesses

  The deal is larger than the small tuck-in acquisitions investors are accustomed to seeing from BSX, making it one factor complicating the BSX narrative.

  Comparison

  Compared with BSX's previous tuck-in deals, this acquisition is larger in scale.

  Risks

  M&A integration, capital allocation, and investor acceptance of a large transaction.

Key data

• US Medtech Performance Relative to the S&P 500Underperformed by about 4,600 bps over the past 12 months; also described in the report as close to 5,000 bpsThe report says medtech is one of the worst-performing groups within healthcare subsectors.
• Sector Valuation CompressionP/E multiple down about 30% since November 2025The report says the current level is near a multi-year low, with the last similarly depressed period dating back to before 2017.
• Valuation Changes in Covered NamesMost names saw multiples decline 25%-60% over the past 18 monthsExhibit 4 shows that P/E or P/S multiples for multiple companies have fallen meaningfully relative to historical averages and late-2024 levels.
• BSX Valuation ChangeP/E fell from above 36x in early 2025 to the current 12.5xSlowing Watchman and EP growth at BSX, lowered guidance, and concerns over the Penumbra/MiRus deals are key sources of pressure on the sector.
• PODD Share Price PerformanceAbout -46% year to datePressure comes from competition, concerns over pharmacy channel pricing, and multiple voluntary medical device correction events.
• ISRG 1Q26 ResultsSales growth of 23%, EPS growth of 38%Fundamentals are strong, but after the sector's valuation reset lower, investors remain valuation-sensitive to its roughly 36x P/E.
• Ticker Table RatingsABT, BSX, DXCM, PODD, ISRG, MDLN, MDT, SYK are O; EW, JNJ, TNDM, ZBH are MO stands for Outperform, and M stands for Market-Perform.

Impact & implications

The investment implication of the report is that the medtech sector has been repriced from a high-visibility growth asset into an asset with execution blemishes and narrative noise, but fundamental evidence does not support a broad bearish view. If concentration in AI-theme returns declines, the market rotates, or company-specific risks are gradually absorbed, medtech companies with quality, innovation, and lower valuations may see a recovery in risk-reward. In the short term, volatility from company-specific events, guidance credibility, and limited investor patience still needs to be absorbed.

Risks

• If procedure volumes or healthcare utilization genuinely slow in 2H26, that could validate investor concerns about industry demand.
• If higher oil, resin, semiconductor, memory, and freight costs persist, they could compress gross margins for medical device companies.
• Rising penetration of GLP-1 weight-loss drugs could affect some end markets such as bariatric surgery, diabetes, and sleep apnea.
• If company-specific execution risks at BSX, ABT, SYK, PODD, MDT, and others continue to worsen, recovery in sector confidence will be delayed.
• If AI-related assets continue to dominate market returns, capital may keep ignoring sectors like medtech with more complicated narratives.
• FDA communications, recalls, cybersecurity issues, M&A integration, and supply chain events may continue to cause short-term stock price shocks.

What to watch

• Whether the AI theme cools and whether market breadth and sector rotation improve.
• Whether SYK can restore investor confidence in its post-cyberattack execution capability through strong second-quarter results.
• Whether ABT's nutrition business returns to growth in 2H26, whether its structural heart business stabilizes, and whether the market reprices the growth opportunity in CGM.
• Whether ISRG's product portfolio including dV5, Ion, SP, XiR, and AI continues to drive strong quarterly performance and upward revisions to earnings expectations.
• When BSX's Watchman and EP growth bottom, and whether its reset long-term growth plan becomes credible.
• Whether oil, freight, resin, semiconductor, and memory costs begin to materially affect medtech gross margins.
• The real impact of GLP-1 expansion on diabetes, obesity, sleep apnea, and related medical device end markets.